Immatics Biotechnologies Gmbh Stock Fundamentals
| IMTXW Stock | USD 0.41 0.01 2.38% |
immatics biotechnologies GmbH fundamentals help investors to digest information that contributes to Immatics Biotechnologies' financial success or failures. It also enables traders to predict the movement of Immatics Stock. The fundamental analysis module provides a way to measure Immatics Biotechnologies' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Immatics Biotechnologies stock.
At this time, Immatics Biotechnologies' Net Interest Income is fairly stable compared to the past year. Interest Income is likely to climb to about 14.5 M in 2024, whereas Interest Expense is likely to drop slightly above 789.5 K in 2024. Immatics | Select Account or Indicator |
immatics biotechnologies GmbH Company Profit Margin Analysis
Immatics Biotechnologies' Profit Margin measures overall efficiency of a company and shows its ability to withstand competition as well as defend against adverse conditions such as rising costs, falling prices, decline in sales or management distress. Profit margin tells investors how well the company executes on its overall pricing strategies as well as how effective the company in controlling its costs.
Current Immatics Biotechnologies Profit Margin | (1.04) % |
Most of Immatics Biotechnologies' fundamental indicators, such as Profit Margin, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, immatics biotechnologies GmbH is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
In a nutshell, Profit Margin indicator shows the amount of money the company makes from total sales or revenue. It can provide a good insight into companies in the same sector, as well as help to identify trends of a company from year to year.
| Competition |
Immatics Pretax Profit Margin
Pretax Profit Margin |
|
Based on the latest financial disclosure, immatics biotechnologies GmbH has a Profit Margin of -1.0401%. This is much lower than that of the Biotechnology sector and significantly lower than that of the Health Care industry. The profit margin for all United States stocks is notably higher than that of the company.
Immatics Biotechnologies Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Immatics Biotechnologies's current stock value. Our valuation model uses many indicators to compare Immatics Biotechnologies value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Immatics Biotechnologies competition to find correlations between indicators driving Immatics Biotechnologies's intrinsic value. More Info.immatics biotechnologies GmbH is currently regarded as number one stock in return on equity category among its peers. It is rated second overall in return on asset category among its peers . At this time, Immatics Biotechnologies' Return On Equity is fairly stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value Immatics Biotechnologies by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.Immatics Profit Margin Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Immatics Biotechnologies' direct or indirect competition against its Profit Margin to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Immatics Biotechnologies could also be used in its relative valuation, which is a method of valuing Immatics Biotechnologies by comparing valuation metrics of similar companies.Immatics Biotechnologies is currently under evaluation in profit margin category among its peers.
Immatics Biotechnologies Current Valuation Drivers
We derive many important indicators used in calculating different scores of Immatics Biotechnologies from analyzing Immatics Biotechnologies' financial statements. These drivers represent accounts that assess Immatics Biotechnologies' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Immatics Biotechnologies' important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 583.4M | 423.8M | 743.6M | 546.8M | 767.3M | 480.3M | |
| Enterprise Value | 483.3M | 222.4M | 620.4M | 412.8M | 564.3M | 373.5M |
Immatics Fundamentals
| Return On Equity | -0.24 | ||||
| Return On Asset | -0.12 | ||||
| Profit Margin | (1.04) % | ||||
| Operating Margin | (1.42) % | ||||
| Number Of Shares Shorted | 736 | ||||
| Revenue | 54 M | ||||
| EBITDA | (88.93 M) | ||||
| Net Income | (96.99 M) | ||||
| Total Debt | 15.4 M | ||||
| Book Value Per Share | 2.66 X | ||||
| Cash Flow From Operations | 18.23 M | ||||
| Number Of Employees | 542 | ||||
| Beta | 0.78 | ||||
| Market Capitalization | 673 M | ||||
| Total Asset | 509.96 M | ||||
| Retained Earnings | (597.29 M) | ||||
| Working Capital | 292.82 M | ||||
| Net Asset | 509.96 M |
About Immatics Biotechnologies Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze immatics biotechnologies GmbH's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Immatics Biotechnologies using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of immatics biotechnologies GmbH based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.| Last Reported | Projected for Next Year | ||
| Current Deferred Revenue | 100.4 M | 70.8 M | |
| Total Revenue | 54 M | 57.8 M | |
| Cost Of Revenue | 118.7 M | 92.4 M | |
| Stock Based Compensation To Revenue | 0.38 | 0.33 | |
| Sales General And Administrative To Revenue | 0.71 | 1.03 | |
| Research And Ddevelopement To Revenue | 2.20 | 3.42 | |
| Capex To Revenue | 0.57 | 0.60 | |
| Revenue Per Share | 0.67 | 0.64 | |
| Ebit Per Revenue | (1.88) | (1.98) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Immatics Stock Analysis
When running Immatics Biotechnologies' price analysis, check to measure Immatics Biotechnologies' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immatics Biotechnologies is operating at the current time. Most of Immatics Biotechnologies' value examination focuses on studying past and present price action to predict the probability of Immatics Biotechnologies' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Immatics Biotechnologies' price. Additionally, you may evaluate how the addition of Immatics Biotechnologies to your portfolios can decrease your overall portfolio volatility.